ArticleThe FEBS journal2025
A patient-derived orthotopic xenograft model unveils metastatic dynamics in head and neck squamous cell carcinoma.
Article in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Modeling metastasis and predicting drug response with malignant effusion-derived organoids: a systematic review and quantitative assessment.Journal of translational medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metastasis presents a significant challenge in head and neck squamous cell carcinoma (HNSC), profoundly impacting patient morbidity and mortality. This proof-of-concept study establishes patient-derived orthotopic xenografts (PDOXs) as an advanced preclinical model to investigate and address metastatic HNSC. Indeed, PDOXs demonstrate noteworthy histopathological and molecular fidelity to primary HNSC tumours. Contrary to the traditional subcutaneous xenografts, PDOXs authentically replicate local lymph node metastasis, mirroring the intricate site-specific cancer-stroma interaction and the disease progression in patients. Furthermore, genomic and transcriptomic analyses underscore the genetic accuracy and heightened resemblance of PDOXs to patient tumours. Notably, nuclear factor kappa-B (NF-κB)-signalling-induced inflammation emerges as a key driver of the metastatic process, unveiling an inflammatory signature with potential implications as a prognostic marker and therapeutic target. These findings underscore the pivotal role of the PDOX model in capturing the complex biology of HNSC, providing insights for precision-targeted therapies and enhancing patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.